Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
! X: p& {) ^( `, d: F, V
1 Z/ V* x3 `% c* |4 a+ w; @6 t) ~& E
6 D& ?, s/ h- F* Z$ }Sub-category:
2 d6 _# a% e; n! ?Molecular Targets
. n5 I ~5 ~* H; A Y; L; c1 @
~( h2 h1 E& Z& [0 S; M9 X6 U; ?
3 O' F+ |# |5 }7 e( V& u, A7 g$ {Category:
9 I) ^7 V2 N1 I8 ITumor Biology
7 Q. x5 F3 D( J. S' }. t+ p& B$ ]8 x! {
0 z* R6 \# z# P! R' Z7 C) _+ c) |2 r Q3 l( P0 s
Meeting:3 h% K5 `/ V. C+ d0 \
2011 ASCO Annual Meeting 4 W8 s8 Q D$ p1 l: c: ^) l! O
+ j1 O- K, Z0 f- f: I9 n6 ^2 W) \+ x& P z
Session Type and Session Title:: W) Z9 a* d/ M
Poster Discussion Session, Tumor Biology - o8 f! h9 R9 T
, G( d( p% K( Y2 u" ] B! X; B7 N+ }1 m
- P6 k& \$ ~: |) h r4 U) F
Abstract No:2 H M- D. S5 l: h8 C0 t# ]
10517
% x" u- \! \/ q
) ]. M, s, W- p
) W% h7 ]/ \1 R; \ \, k' h$ |, FCitation:1 ~1 `; [( d4 d
J Clin Oncol 29: 2011 (suppl; abstr 10517)
* z5 ^, l5 F) X- E- t/ E2 ~$ ~! p& U. \# \% P% X! J) i
9 e: j( E& W4 w+ E5 y# JAuthor(s):
1 o: I. q6 @- f0 G& f- N9 RJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
1 P) |/ m+ A: o% O) \; x' n1 S
# n Z% {3 E& M9 t+ p( X
6 s) c! R4 @- D5 z Z3 R1 k4 Z3 T" o% }& q8 v9 ^' w5 k
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.0 C d, p2 F. `: _6 @
: E5 w% v* ]+ o6 J8 sAbstract Disclosures" y2 u: p. k( d" u1 ~5 y" Z" D
! q; }& y7 M; G4 \, g; D' cAbstract:
" R( S+ m. o1 Y' w9 T5 j N8 k! Y7 c' |+ v
9 q9 I: @$ A0 ?- b u! |Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
) \# o$ q0 {& ^# l$ I3 y: r4 \) Y8 p0 n% l R- N. M% F
5 H) n- [) `3 k& W
|